Robert W. Baird Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on Apellis Pharmaceuticals (APLSResearch Report) on July 19 and set a price target of $90.00. The company’s shares closed last Thursday at $52.60.

According to, Kusy is ranked 0 out of 5 stars with an average return of -37.5% and a 16.1% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Karyopharm Therapeutics, and Mersana Therapeutics.

Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $76.70, which is a 51.8% upside from current levels. In a report issued on July 19, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.38 million and GAAP net loss of $139 million. In comparison, last year the company had a GAAP net loss of $184 million.

Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Read More on APLS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More